A5075129443- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- interferon and immune responses
- Immunotherapy and Immune Responses
- HIV/AIDS drug development and treatment
- Viral gastroenteritis research and epidemiology
- Immune Response and Inflammation
- HIV Research and Treatment
- RNA modifications and cancer
- Viral Infectious Diseases and Gene Expression in Insects
- Biochemical and Molecular Research
- Bacteriophages and microbial interactions
- Viral Infections and Outbreaks Research
- Immune Cell Function and Interaction
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- Animal Disease Management and Epidemiology
- Virus-based gene therapy research
- RNA Research and Splicing
- Insect Resistance and Genetics
- Epigenetics and DNA Methylation
- Viral Infections and Immunology Research
- Monoclonal and Polyclonal Antibodies Research
Université Claude Bernard Lyon 1
2016-2025
Inserm
2016-2025
Centre National de la Recherche Scientifique
2016-2025
École Normale Supérieure de Lyon
2008-2025
Centre International de Recherche en Infectiologie
2021-2025
Centre de Recherche en Cancérologie de Lyon
2014-2023
Centre Léon Bérard
2016-2023
Cancer Research Center
2019-2020
Hôpital de la Croix-Rousse
2017
Hospices Civils de Lyon
2007-2017
Current antiviral agents can control but not eliminate hepatitis B virus (HBV), because HBV establishes a stable nuclear covalently closed circular DNA (cccDNA). Interferon-α treatment clear is limited by systemic side effects. We describe how interferon-α induce specific degradation of the viral without hepatotoxicity and propose lymphotoxin-β receptor activation as therapeutic alternative. up-regulated APOBEC3A APOBEC3B cytidine deaminases, respectively, in HBV-infected cells, primary...
Mutations within the hepatitis B virus (HBV) polymerase gene conferring drug-resistance are selected during prolonged lamivudine (3TC) or adefovir dipivoxil (ADV) treatment. Because there is no other approved drug against HBV, treatments with 3TC ADV used either sequentially in addition, depending on treatment response failure. Considering use of de novo add-on 3TC+ADV bitherapy, we investigated possibility emergence an HBV strain harboring mutations resistance to both (rtL180M+M204V) and...
Chronic hepatitis B and D infections are major causes of liver disease hepatocellular carcinoma worldwide. Efficient therapeutic approaches for cure absent. Sharing the same envelope proteins, virus delta use sodium/taurocholate cotransporting polypeptide (a bile acid transporter) as a receptor to enter hepatocytes. However, detailed mechanisms viral entry process still poorly understood. Here, we established high-throughput infectious cell culture model enabling functional genomics...
The recently described hepatic cell line HepaRG is the sole hepatoma susceptible to hepatitis B virus (HBV) infection. It provides a unique tool for investigating some unresolved issues of virus' biology, particularly formation viral mini-chromosome believed be responsible persistence In this study, we characterized main features HBV infection: it restricted subpopulation differentiated hepatocyte-like cells that express albumin as functional marker and represents around 10 % all cells....
Hepatitis B virus (HBV) is currently viewed as a stealth that does not elicit innate immunity in vivo. This assumption has yet been challenged vitro because of the lack relevant cell culture system. The HepaRG line, which physiologically closer to differentiated hepatocytes and permissive HBV infection, opened new perspectives this respect.HBV baculoviruses were used initiate an replication both HepG2 cells. To monitor replication, synthesis encapsidated DNA, secretion hepatitis surface...
Chronic hepatitis B virus (HBV) infection is a major factor in hepatocellular carcinoma (HCC) pathogenesis by mechanism not yet understood. Elucidating mechanisms of HBV-mediated hepatocarcinogenesis needed to gain insights into classification and treatment HCC. In HBV replicating cells, including virus-associated HCCs, suppressor zeste 12 homolog (SUZ12), core subunit Polycomb repressive complex2 (PRC2), undergoes proteasomal degradation. This process requires the long noncoding RNA, Hox...
The assembly of hepatitis B virus (HBV) core protein (HBc) into capsids represents a critical step viral replication. HBc has multiple functions during the HBV life cycle, which makes it an attractive target for antiviral therapies. Capsid modulators (CAMs) induce formation empty capsid or aberrant devoid pregenomic RNA (pgRNA) and finally block relaxed circular DNA neosynthesis virion progeny. In this study, novel CAMs JNJ-827 JNJ-890 were found to be potent inhibitors replication with...
ABSTRACT The glucose-derived iminosugar derivatives N -butyl- and -nonyl-deoxynojirimycin (DNJ) have an antiviral effect against a broad spectrum of viruses including Bovine viral diarrhea virus (BVDV). For BVDV, this has been attributed to the reduction secretion due impairment morphogenesis caused by ability DNJ-based inhibit ER α-glucosidases (N. Zitzmann, A. S. Mehta, Carrouée, T. D. Butters, F. M. Platt, J. McCauley, B. Blumberg, R. Dwek, Block, Proc. Natl. Acad. Sci. USA...
HCV entry into cells is a multi-step and slow process. It believed that the initial capture of particles by glycosaminoglycans and/or lipoprotein receptors followed coordinated interactions with scavenger receptor class B type I (SR-BI), major high-density (HDL), CD81 tetraspanin, tight junction protein Claudin-1, ultimately leading to uptake cellular penetration via low-pH endosomes. Several reports have indicated HDL promotes through interaction SR-BI. This pathway remains largely elusive,...
ABSTRACT Investigation of the entry pathways hepatitis B virus (HBV), a member family Hepadnaviridae , has been hampered by lack versatile in vitro infectivity models. Most concepts hepadnaviral infection come from more robust duck HBV system; however, whether two viruses use same mechanisms to invade target cells is still matter controversy. In this study, we investigate role an important plasma membrane component, caveolin-1 (Cav-1), infection. Caveolins are main structural components...
Abstract Statins are 3-hydroxyl-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors used for the treatment of hypercholesterolemia. It was recently reported that statins inhibit in vitro hepatitis C virus (HCV) RNA replication. We here report that, five studied, mevastatin and simvastatin exhibit strongest anti-HCV activity, lovastatin fluvastatin have moderate inhibitory effects, pravastatin is devoid an antiviral effect. combination with interferon-alpha (IFN-α) or HCV nonstructural...